ELEdmond Y. Lau

Edmond Y. Lau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edmond Y. Lau has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Engineering an aldoxime dehydratase with high activity and isomer tolerance for biosynthesis of an O-protected primary cyanohydrin

    by Marcus V. Moreno, Daniel J. Wackelin, Erick G. Ortiz, Edmond Y. Lau, Nathaniel B. Zuckerman, Mimi C. Yung

  • Open Access

    Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape

    by Fangqiang Zhu, Saravanan Rajan, Conor F. Hayes, Ka Yin Kwong, Andre R. Goncalves, Adam T. Zemla, Edmond Y. Lau, Yi Zhang, Yingyun Cai, John W. Goforth, et al.

    Most previously authorized clinical antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have lost neutralizing activity to recent variants due to rapid viral evolution. To mitigate such escape, we preemptively enhance AZD3152, an antibody authorized for prophylaxis in immunocompromised individuals. Using deep mutational scanning (DMS) on the SARS-CoV-2 antigen, we identify AZD3152 vulnerabilities at antigen positions F456 and D420. Through two iterations of computational antibody design that integrates structure-based modeling, machine-learning, and experimental validation, we co-optimize AZD3152 against 24 contemporary and previous SARS-CoV-2 variants, as well as 20 potential future escape variants. Our top candidate, 3152-1142, restores full potency (100-fold improvement) against the more recently emerged XBB.1.5+F456L variant that escaped AZD3152, maintains potency against previous variants of concern, and shows no additional vulnerability as assessed by DMS. This preemptive mitigation demonstrates a generalizable approach for optimizing existing antibodies against potential future viral escape.


  • Open Access

    Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants

    by Thomas A. Desautels, Kathryn T. Arrildt, Adam T. Zemla, Edmond Y. Lau, Fangqiang Zhu, Dante Ricci, Stephanie Cronin, Seth J. Zost, Elad Binshtein, Suzanne M. Scheaffer, et al.

    The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs 1–3 , but also revealed how quickly viral escape can curtail effective options 4, 5 . With the emergence of the SARS-CoV-2 Omicron variant in late 2021, many clinically used antibody drug products lost potency, including Evusheld TM and its constituent, cilgavimab 4, 6 . Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is compatible with other antibodies in combination 4 and is challenging to replace with existing approaches. Rapidly modifying such high-value antibodies with a known clinical profile to restore efficacy against emerging variants is a compelling mitigation strategy. We sought to redesign COV2-2130 to rescue in vivo efficacy against Omicron BA.1 and BA.1.1 strains while maintaining efficacy against the contemporaneously dominant Delta variant. Here we show that our computationally redesigned antibody, 2130-1-0114-112, achieves this objective, simultaneously increases neutralization potency against Delta and many variants of concern that subsequently emerged, and provides protection in vivo against the strains tested, WA1/2020, BA.1.1, and BA.5. Deep mutational scanning of tens of thousands pseudovirus variants reveals 2130-1-0114-112 improves broad potency without incurring additional escape liabilities. Our results suggest that computational approaches can optimize an antibody to target multiple escape variants, while simultaneously enriching potency. Because our approach is computationally driven, not requiring experimental iterations or pre-existing binding data, it could enable rapid response strategies to address escape variants or pre-emptively mitigate escape vulnerabilities.


  • Open Access

    Evaluation of polyanionic cyclodextrins as high affinity binding scaffolds for fentanyl

    by Brian P. Mayer, Daniel J. Kennedy, Edmond Y. Lau, Carlos A. Valdez

    Cyclodextrins (CDs) have been previously shown to display modest equilibrium binding affinities (Ka ~ 100–200 M-1) for the synthetic opioid analgesic fentanyl. In this work, we describe the synthesis of new CDs possessing extended thioalkylcarboxyl or thioalkylhydroxyl moieties and assess their binding affinity towards fentanyl hydrochloride. The optimal CD studied displays a remarkable affinity for the opioid of Ka = 66,500 M−1, the largest value reported for such an inclusion complex to date. One dimensional 1H Nuclear Magnetic Resonance (NMR) as well as Rotational Frame Overhauser Spectroscopy (2D-ROESY) experiments supported by molecular dynamics (MD) simulations suggest an unexpected binding behavior, with fentanyl able to bind the CD interior in one of two distinct orientations. Binding energies derived from the MD simulations work correlate strongly with NMR-derived affinities highlighting its utility as a predictive tool for CD candidate optimization. The performance of these host molecules portends their utility as platforms for medical countermeasures for opioid exposure, as biosensors, and in other forensic science applications.


  • Unraveling the relationship between molecular properties and rapid diffusion in smooth nanopores

    by Steven F. Buchsbaum, Sei Jin Park, Melinda L. Jue, April M. Sawvel, Chiatai Chen, Eric Meshot, Marissa Wood, Kuang Jen Wu, Camille Bilodeau, Fikret Aydin, et al.

  • Open Access

    Sequence, Structure, and Epitope Analysis of the Polymorphic Membrane Protein Family in Chlamydia trachomatis

    by Patrick W. Cervantes, Brent Segelke, Edmond Y. Lau, Luis de la Maza, Matthew Coleman, Patrik D’haeseleer

    The polymorphic membrane proteins are a family of autotransporters that play an important role in infection, adhesion and immunity in Chlamydia trachomatis . Here we show that the characteristic GGA(I,L,V) and FxxN tetrapeptide repeats fit into a larger repeat sequence, and that these repeats correspond to the coils of a large beta-helical domain in high quality structure predictions. While the tetranucleotide motifs themselves are predicted to play a structural role in folding and close stacking of the beta-helical backbone of the passenger domain, we found many of the interesting features of Pmps are localized to the side loops jutting out from the beta helix - including protease cleavage, host cell adhesion, and B-cell epitopes; while T-cell epitopes are predominantly found in the beta-helix itself.


  • Solvent effects on nuclear shielding of neon

    by E. Y. Lau, J. T. Gerig

    Computer simulations of neon dissolved in a variety of organic liquids are used to explore the origins of solvent‐induced changes in the neon shielding parameter. Relying on recent theoretical calculations, it is demonstrated that short‐range (van der Waals) interactions between the rare gas atom and solvent molecules are the predominant source of the shielding parameter changes. The treatment used leads to calculated solvent‐induced changes for solvents as diverse as water and hexane that are in good agreement with experimental observations.